This collaboration follows the company's previously announced collaborations with the Cleveland Clinic and University of Texas Southwestern Gene Therapy Program (UTSW) to support the creation of a novel next-generation minigene platform designed to overcome key challenges in gene therapy.

The current collaboration is with Dr. Yong-Hui Jiang, PhD, professor and chief of medical genetics at Yale University. The team of Yale University researchers will create minigene payloads to treat neurodevelopmental disorders, including intellectual disability. Also, UTSW will produce viral vector constructs that incorporate the minigene payloads and evaluate the constructs for in vivo and in vitro efficacy.

As part of the collaboration, Taysha will have an exclusive option on new payloads, constructs, and intellectual property associated with, and arising from, the research conducted under the agreement.

Taysha collaborates on minigene payloads for AAV gene therapy
Taysha Gene Therapies has established multiyear collaborations with the Cleveland Clinic and the University of Texas Southwestern Gene Therapy Program...

Taysha, UTSW start fund to speed up CNS gene therapies
Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated...

AllStripes, Taysha Gene Therapies partner on rare disease gene therapy program
AllStripes and Taysha Gene Therapies have entered a multiyear collaboration focused on advancing the development of TSHA-104, an adeno-associated virus...